HOME >> BIOLOGY >> NEWS
NICHD funded researchers first to genetically modify non human primate

Researchers funded by the National Institute of Child Health and Human Development (NICHD) and the National Center for Research Resources of the National Institutes of Health have completed the first successful effort to introduce a new gene into the unfertilized eggs of rhesus monkeys, a member of the family of mammals that includes human beings. The eggs were then fertilized, resulting in several pregnancies and the birth of three live monkeys. The gene was successfully incorporated into one monkey's DNA, making this the first genetically modified non-human primate. Previous gene transfer attempts in animals have been confined largely to rodents and agricultural animals.

The technology could lead to the development of a variety of animal models of diseases having a greater resemblance to the corresponding human conditions than do any animal models now in existence. The new accomplishment could also provide insights into human diseases and to techniques for treating a variety of human disorders, from cancer, to cystic fibrosis, to Alzheimer's disease, to birth defects, to heart disease, to AIDS. The finding, which appears in the current issue of Science, was reported by Gerald Schatten, Ph.D., and his coworkers at the Oregon Regional Primate Research Center at the Oregon Health Sciences University in Portland, Oregon.

"This research breaks a technical barrier," said NICHD Director Duane Alexander, M.D. "The technology paves the way for developing new models for testing treatments for a variety of diseases in a more relevant way than is currently possible."

Although scientists have often inserted genes into other animals, they have lacked the technical means to introduce new genes into primates. These researchers succeeded by adapting to rhesus monkeys a technology that previously was used for transferring genes to cattle. The Oregon group transferred a gene for green fluorescent protein (GFP) into the egg cells of rhesus monkeys. As its na
'"/>

Contact: Bob Bock
rb96a@nih.gov
301-496-5133
NIH/National Institute of Child Health and Human Development
10-Jan-2001


Page: 1 2

Related biology news :

1. NICHD Researchers Discover Gene For Major Brain Structure
2. Should publicly funded research be free and available to the public?
3. RSRF-funded study leads to breakthrough for Rett Syndrome research
4. NIEHS-funded researchers find low-level ozone increases respiratory risk of asthmatic children
5. Interdisciplinary coral bleaching research funded
6. EMBO to coordinate EU funded project to support science teachers
7. NSF-funded researchers track Alaska seal migration for the first time
8. Research funded to develop plant-based diabetes treatment
9. Research funded to test new breast cancer medicine
10. NSF-funded scientists to examine environment at the molecular level
11. NSF-funded researchers discover evidence of microscopic life at the South Pole

Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: